#Gold #FTSE Reviewing Astrazeneca 6 months ago, we provided a fairly optimistic final paragraph, most of which has come to fruition and an update is needed. Now the recipient of 8 booster shots for Covid-19, recently was able to tick off 6 of the 7 symptoms for catching the illness. Quite literally, everything cleared up within around 12 hours, substantially faster than the previous 3 days of discomfort and suggesting the virus makers have managed to accelerate the speed at which their “stuff” kicks in.
While lots of people now eschew the vaccine for various reasons, personally I don’t really have a choice due to a seriously compromised immune system. In an almost funny state of affairs, a recent visit to “The Unit” drained an armful of blood for a complete lab analysis. Apparently, I am now normal, bloodwork saying no leukaemia is present, my immune system is working, my heart is tickety-boo, my blood pressure is perfect and there’s no sign of my T2 Diabetes. It was all good news, only slightly diluted by the reality of taking 17 different pills a day to treat my little range of issues. Thankfully the current daily chemo hasn’t caused any new side effects, the horrible range of medications necessary due to a particular brand of chemo provoking just about everything on the makers list of potential whoopsies.
Unfortunately, the consultant warned of the glaringly obvious. Just because I test as “normal”, one needs remember it’s due to the range of drugs. As a result, it would be frowned upon if I did something “not normal” like go skiing, go out for a run, take up cycling, return to swimming, or wander into the forest with my chainsaw to hunt trees. Being “normal” can be a little boring, to be honest, though I sometimes wonder if I’m a victim of Big Pharma, a cancer drug causing a series of nuisance problems but don’t worry, we’ve a drug for that! A repeat prescription form which is reminiscent of “Good Old Yellow Pages” isn’t something to be proud of. But on the bright side, recently attending a function with many friends and family was nice, constantly complimented for looking great.
To be clear, Astrazeneca were NOT the supplier of the chemotherapy which consigned me to “normal”, nor do they seem to be the supplier of choice (here in Argyll) for Covid-19 boosters. Only the first injection back in 2000 was sourced from this UK company, all others since coming from Pfizer.
Astrazeneca Plc are one of the more impressive penny shares, current trading at around 11,158 pennies at time of writing. Or more recognisably, £111 quid per share, thanks to strong Earnings in the second quarter of this year. Their share price behaviour has been assigned to successful cancer drugs and from a personal perspective, the last 15 years has seen astounding improvements in effectiveness, despite a residual hatred of a particular chemo which assigned me to live a “normal” life. While this may sound ungrateful from someone who happily spends hours at a desk, playing with software ideas and monitoring the markets, it took an age until the discovery of how (relatively) easy it could be to make successful wine. Alternately, there is always our shooting range and most recently, a vegetable garden plot is producing carrots, potatoes, peas, and questionable onions.
The immediate situation is interesting, suggesting share price movement above 11,225 should trigger a rise to an initial 12,001 and some very probable hesitation. Our secondary, should the 120 quid level be exceeded, calculates at an eventual 13,181 pence. Goodness knows how long such a movement may take as this secondary challenges the highs of 2024.
The share price needs dip below the 10,000p level to indicate trouble, giving a hint of coming weakness to an initial 9,187 with our secondary, if broken, at a less likely 8,132p.
FUTURES
FUTURES
| Time Issued | Market | Price At Issue | Short Entry | Fast Exit | Slow Exit | Stop | Long Entry | Fast Exit | Slow Exit | Stop | Prior |
| 10:30:04PM | BRENT | 7176.1 | Success | ||||||||
| 10:50:16PM | GOLD | 3326.02 | 3307 | 3295 | 3282 | 3322 | 3334 | 3340 | 3351 | 3323 | |
| 10:52:38PM | FTSE | 9140.4 | 9078 | 9051 | 9014 | 9101 | 9157 | 9169 | 9182 | 9122 | |
| 10:54:37PM | STOX50 | 5376 | ‘cess | ||||||||
| 10:57:46PM | GERMANY | 24209.3 | ‘cess | ||||||||
| 11:04:10PM | US500 | 6373 | ‘cess | ||||||||
| 11:07:10PM | DOW | 44631 | Success | ||||||||
| 11:09:13PM | NASDAQ | 23329.3 | Success | ||||||||
| 11:11:43PM | JAPAN | 40669 |
29/07/2025 FTSE Closed at 9136 points. Change of 0.61%. Total value traded through LSE was: £ 5,656,845,157 a change of 28.68%
28/07/2025 FTSE Closed at 9081 points. Change of -0.43%. Total value traded through LSE was: £ 4,395,992,123 a change of -22.42%
25/07/2025 FTSE Closed at 9120 points. Change of -0.2%. Total value traded through LSE was: £ 5,666,736,165 a change of 2.7%
24/07/2025 FTSE Closed at 9138 points. Change of 0.85%. Total value traded through LSE was: £ 5,517,760,836 a change of 0.27%
23/07/2025 FTSE Closed at 9061 points. Change of 0.42%. Total value traded through LSE was: £ 5,503,107,449 a change of 15.9%
22/07/2025 FTSE Closed at 9023 points. Change of 0.11%. Total value traded through LSE was: £ 4,748,177,940 a change of -18.75%
21/07/2025 FTSE Closed at 9013 points. Change of 0.23%. Total value traded through LSE was: £ 5,844,177,797 a change of 22.54% 
SUCCESS above means both FAST & SLOW targets were met. ‘CESS means just the FAST target met and probably the next time it is exceeded, movement to the SLOW target shall commence.
Our commentary is in two sections. Immediately below are today’s updated comments. If our commentary remains valid, the share can be found in the bottom section which has a RED heading. Hopefully, this will mean you no longer need to flip back through previous reports. HYPERLINKS DISABLED IN THIS VERSION
Please remember, all prices are mid-price (halfway between the Buy and Sell). When we refer to a price CLOSING above a specific level, we are viewing the point where we can regard a trend as changing. Otherwise, we are simply speculating on near term trading targets. Our website is www.trendsandtargets.com.
UPDATE. We often give an initial and a secondary price. If the initial is exceeded, we still expect it to fall back but the next time the initial is bettered, the price should continue to the secondary. The converse it true with price drops.
We can be contacted at info@trendsandtargets.com. Spam filters set to maximum so only legit emails get through…
Section One – Outlook Updated Today. Click here for Section Two – Outlook Remains Valid shares
Click Epic to jump to share: LSE:AVCT Avacta** **LSE:BARC Barclays** **LSE:BME B & M** **LSE:GRG Greggs** **LSE:HSBA HSBC** **LSE:ITM ITM Power** **LSE:RKH Rockhopper** **LSE:STAN Standard Chartered** **
********
Updated charts published on : Avacta, Barclays, B & M, Greggs, HSBC, ITM Power, Rockhopper, Standard Chartered,
LSE:AVCT Avacta. Close Mid-Price: 54.5 Percentage Change: + 14.74% Day High: 54.5 Day Low: 44.5
Target met. In the event of Avacta enjoying further trades beyond 54.5, t ……..
</p
View Previous Avacta & Big Picture ***
LSE:BARC Barclays. Close Mid-Price: 371.2 Percentage Change: + 2.77% Day High: 372.7 Day Low: 355.2
Target met. All Barclays needs are mid-price trades ABOVE 372.7 to improv ……..
</p
View Previous Barclays & Big Picture ***
LSE:BME B & M Close Mid-Price: 226.9 Percentage Change: -0.04% Day High: 229 Day Low: 218.3
In the event B & M experiences weakness below 218.3 it calculates with a ……..
</p
View Previous B & M & Big Picture ***
LSE:GRG Greggs Close Mid-Price: 1567 Percentage Change: -4.74% Day High: 1640 Day Low: 1499
Target met. Continued weakness against GRG taking the price below 1499 ca ……..
</p
View Previous Greggs & Big Picture ***
LSE:HSBA HSBC. Close Mid-Price: 970 Percentage Change: + 1.06% Day High: 975.8 Day Low: 959.2
Continued trades against HSBA with a mid-price ABOVE 975.8 should improve ……..
</p
View Previous HSBC & Big Picture ***
LSE:ITM ITM Power Close Mid-Price: 58.2 Percentage Change: -11.01% Day High: 65.4 Day Low: 57.1
If ITM Power experiences continued weakness below 57.1, it will invariabl ……..
</p
View Previous ITM Power & Big Picture ***
LSE:RKH Rockhopper. Close Mid-Price: 73.8 Percentage Change: + 0.00% Day High: 76.4 Day Low: 72.6
Target met. Further movement against Rockhopper ABOVE 76.4 should improve ……..
</p
View Previous Rockhopper & Big Picture ***
LSE:STAN Standard Chartered. Close Mid-Price: 1365.5 Percentage Change: + 2.32% Day High: 1366 Day Low: 1342
Further movement against Standard Chartered ABOVE 1366 should improve acc ……..
</p
View Previous Standard Chartered & Big Picture ***